Fact CheckerSign in

NCT05907694Recruiting

Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure

Medical Treatment With or Without Transcatheter Patent Foramen Ovale CloSure for Older Patients With CrypTogenic StrOke and Patent Foramen Ovale. The STOP Trial

Source: ClinicalTrials.gov · Last updated 27 Mar 2026

Brief summary (registry, in English)

Patent foramen ovale PFO closure has been shown to reduce the risk of stroke in patients with recurrent stroke. However, the majority of existing clinical studies in this field excluded patients over the age of 60 years. Data in older patients is limited and since the population ages and stroke remains a major cause of death and morbidity, randomized clinical trials are needed to better assess the benefit of PFO closure in this elderly population. Therefore, this study proposal sought to determine the efficacy of PFO closure for the prevention of recurrent stroke in older patients with PFO and cryptogenic stroke.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
714 (estimated)
First submitted
8 Jun 2023
Start date
18 Jun 2024
Primary completion date
1 Oct 2027
Lead sponsor
Josep Rodes-Cabau
Diseases
Stroke
NCT number
NCT05907694

What you commit to

  • Study type: Interventional
  • Planned participants: 714
  • From 18 Jun 2024 to the primary completion date, 1 Oct 2027
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Need for chronic anticoagulation therapy.
  • Any contraindication for antiplatelet therapy (aspirin, clopidogrel, ticagrelor).
  • History of prior valve surgery or transcatheter valve repair.
  • Prior surgical or endovascular treatments of PFO or ASD.

Other illness

  • Lacunar (small vessel) stroke.
  • Uncontrolled hypertension (systemic pressure values \>160/90 mmHg despite optimal medical treatment).
  • History of myocardial infarction or coronary intervention. (percutaneous coronary intervention, coronary artery bypass graft).
  • Presence of deep venous thrombosis at the time of index stroke as evaluated by Doppler ultrasonography.
  • Significant (moderate or severe) valvular disease as evaluated by echocardiography.
  • History of congestive heart failure.
  • Other specific cause of stroke identified (eg, arteritis, dissection, migraine/vasospasm, and drug abuse).
  • Rheumatic heart disease.
  • Active cancer.
  • Severe pulmonary artery hypertension (systolic pulmonary pressure \>60 mmHg).
  • Failure to provide signed informed consent.

Lab values

  • Left ventricular ejection fraction \<50% as evaluated by TTE.

Age

  • Any medical condition determining a life expectancy \<2 years.

Other

  • -≤60 year-old
  • Permanent or paroxysmal atrial fibrillation/flutter (clinically apparent or detected by continuous ECG monitoring).
  • Presence of extracranial or intracranial atherosclerosis causing ≥50% luminal --stenosis in arteries supplying the area of ischemia.
  • Presence of complex atheroma plaques at the ascending aorta-aortic arch (≥4-mm-thick, ulcerated or containing mobile thrombi) as evaluated by TEE.
  • Presence of intracardiac thrombus as evaluated by TEE.
  • Severe chronic kidney dysfunction defined an estimated glomerular filtration rate \<30 ml/min/m2 or need for dialysis.
  • Isolated ASD or ASD associated with PFO but with a hemodynamically significant left-to-right shunt requiring closure.
  • Left atrial enlargement defined as a left atrial diameter \>41 mm in men and ≥39 mm in women.
  • Presence of high burden of premature atrial contractions (\>500 per 24 hrs) as evaluated by continuous ECG monitoring.
  • Follow-up impossible or expected poor compliance.
  • Presence of an inferior vena cava filter.
  • Functional dependency as measured by a modified Rankin Scale score \>3 (unable to attend to own bodily needs without assistance and unable to walk unassisted).
  • Participation in another randomized study.

Who the study is looking for

  • Cryptogenic stroke
  • Age \>60 years
  • Right-to-left shunt as evaluated by echocardiography (TEE).

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
IUCPQ
Coordinator of this site? Confirm its status
QuébecCanadaRecruiting
IUCPQ-UL
Coordinator of this site? Confirm its status
QuébecCanadaActive, not recruiting

This page is information, not medical advice. Discuss any trial with your doctor.